To read more content about aviNews España ENG

Content available in:
Español (Spanish)

  • What is phage therapy and what is its use in poultry?

Intensive production in the poultry sector will be at an estimated 132 million tons of chicken meat by 2026. The only feasible way to achieve this growth will be by adopting strategies that allow the control and prevention of infections with a significant economic impact.

In 2018, the two most common zoonoses in humans in the European Union (EU) were caused by Campylobacter and Salmonella with a total of 246,571 and 91,857 cases, respectively. In this same year, the incidence of infection (per 100,000 inhabitants) in the United States was 19.5 for Campylobacter and 18.3 for Salmonella. The cause in most cases was the consumption of contaminated products derived from poultry.

Both Campylobacter and many Salmonella enterica serotypes do not cause diseases in birds. However, S. Gallinarum or S. Pullorum or certain strains of Escherichia coli are responsible for infections that cause significant economic losses in the sector.

Ceva Int 2022

To avoid this, there has been an abuse and misuse of antibiotics, which has contributed to the emergence of multi-resistant bacterial pathogens to antibiotics that are rendered ineffective in the treatment of certain bacterial infections in both humans and animals. In this sense, the EU, following the latest recommendations of the World Health Organization (WHO), has approved a regulation with application in 2022, further limiting the preventive use of antibiotics in poultry farming.

  • Its natural origin
  • High specificity
  • The non-involvement of the commensal microbiota
  • Self-replication capability
  • Low involvement of host cells

However, they also have some disadvantages such as:

Cobbcares INT
Liptosa INT 2022
Ceva Int 2022
WVEPAH

These limitations can be overcome by using bacteriophage cocktails that recognize different bacterial receptors or encapsulate them to protect them.

The efficacy of phage therapy in poultry for the control of infections caused by Campylobacter, Salmonella and E. coli has been previously reviewed. This article summarizes advances made in the last 6 years with reference to the use of non-encapsulated and encapsulated bacteriophages (Table 1).

Most of the studies are experimental in nature and the effectiveness of phage therapy is uneven, influenced by different factors such as the type of microorganism, the age of the animals, the route and time of administration of the bacteriophages or individual characteristics of the phage or its specificity. 




TO CONTINUE READING REGISTER IT IS COMPLETELY FREE


Access to articles in PDF
Keep up to date with our newsletters
Receive the magazine for free in digital version




REGISTRATION




ACCESS
YOUR ACCOUNT







LOGIN


Lost your password?




 

Ceva Int 2022
Liptosa INT 2022
Cobbcares INT
WVEPAH
MORE ABOUT Pathology

JOIN OUR POULTRY COMMUNITY

Access the PDF articles
Keep up to date with our newsletters
Receive the magazine for free in digital version

DISCOVER
AgriFM - The Livestock Sector Podcasts in English
agriCalendar - The events calendar of the agricultural worldagriCalendar
agrinewsCampus - Training courses for the livestock sector